Thursday, January 28, 2021

12:50-13:00 Welcome

SESSION I – Etiology of MDS
Chairs: Charlotte Niemeyer (Freiburg) & Austin Kulasekararaj (London)

13:00-13:05 Introduction
Charlotte Niemeyer (Freiburg)
Austin Kulasekararaj (London)

13:05-13:20 Therapy related MDS and other environmental factors in MDS
Maria Teresa Voso (Rome)

13:20-13:35 Genetic predisposition to MDS and acute leukaemia
Charlotte Niemeyer (Freiburg)

13:35-13:50 CHIP / functional implications in MDS and AML
Austin Kulasekararaj (London)

13:50-14:05 Inflammation of HSCs as a potential driver of ineffective hematopoiesis
Marieke Essers (Heidelberg)

14:05-14:20 Relationships between inherited and acquired predisposition
Jaroslaw Maciejewski (Cleveland)

SHORT COMMUNICATIONS:

14:20-14:30 Leukemogenesis in GATA2 Haploinsufficient Mice Occurs Secondary to Bone Marrow Failure
Miriam Erlacher (Freiburg)

14:30-14:40 The Genomic Landscape of Myeloid Neoplasms Evolved from Aplastic Anemia/Paroxysmal Nocturnal Hemoglobinuria
Carmelo Gurnari (Cleveland)

14:40-15:10 Panel discussion

15:10-15:20 Coffee Break
SESSION II – Biology of MDS – Genetic Abnormalities
Chairs: Maria (Ken) Figueroa (Miami) & Mikkael Sekeres (Miami)

15:20-15:25 Introduction  Maria (Ken) Figueroa (Miami)  Mikkael Sekeres (Miami)

15:25-15:40 Review of currently available pre-clinical models (including zebra fish) of MDS  Daniel Nowak (Mannheim)

15:40-15:55 Multiple acquired clonal steps to MDS, molecular architecture and its progression to AML  Olivier Kosmider (Paris)

15:55-16:10 Druggable molecular targets in MDS and elderly AML (IDH, TP53… )  Torsten Haferlach (Munich)

16:10-16:25 Epigenetic abnormalities in MDS and their relationship with somatic mutations  Maria (Ken) Figueroa (Miami)


SHORT COMMUNICATION:

16:40-16:50 Impact of Somatic Mutations in Myelodysplastic Patients with Isolated Partial or Total Loss of Chromosome 7  Elena Crisà (Novara)

16:50-17:20 Panel discussion

17:25-18:25 SATELLITE SYMPOSIUM:

Title: Ineffective Erythropoiesis: Understanding the biology, optimising clinical practice
Chair: Uwe Platzbecker (Leipzig)
Speakers: Michaela Fontenay (Paris) & Paresh Vyas (Oxford)

MDS Satellite Symposium organized and funded by Celgene | A Bristol Myers Squibb Company

SESSION III – Biology of MDS: Stem Cells and the Microenvironment
Chairs: Hind Medyouf (Frankfurt) & Uwe Platzbecker (Leipzig)

18:30-18:35 Introduction  Hind Medyouf (Frankfurt)  Uwe Platzbecker (Leipzig)

18:35-18:50 The niche in MDS: Inflammation driving evolution  Marc H.G.P. Raaijmakers (Rotterdam)

18:50-19:05 Bone biology and the osteo-hematopoietic niche  Ulrike Baschant (Dresden)


19:20-19:35 Mesenchymal stem cells in MDS: The better targets?  Hind Medyouf (Frankfurt)
LIVE Programme
CET Time


19:50-20:20  Panel discussion

20:20-20:55  Controversial debate
Genetics versus epigenetics in myeloid disease?
Chair: Uwe Platzbecker (Leipzig)

Audience voting

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>20:20-20:25</td>
<td>Introduction</td>
<td>Uwe Platzbecker (Leipzig)</td>
</tr>
<tr>
<td>20:25-20:35</td>
<td>Genetics</td>
<td>Torsten Haferlach (Munich)</td>
</tr>
<tr>
<td>20:35-20:45</td>
<td>Epigenetics</td>
<td>Maria (Ken) Figueroa (Miami)</td>
</tr>
</tbody>
</table>

Audience voting

20:45-20:55  Discussion

Friday, January 29, 2021

13:00-14:00  3 Simultaneous Meet the Expert sessions
Flow cytometry in MDS
Technical aspects: cytogenetic and mutational analysis
Analysis of somatic mutations, of SNP etc.

Arjan van de Loosdrecht (Amsterdam)
Torsten Haferlach (Munich)
Luca Malcovati (Pavia)

SESSION IV – Diagnostic Workup and Prognostic Factors in MDS
Chairs: Ari Giagounidis (Düsseldorf) & Felicitas Thol (Hannover)

14:05-14:10  Introduction
Ari Giagounidis (Düsseldorf)
Felicitas Thol (Hannover)

14:10-14:25  Morphology (including WHO 2018 classification),
cytogenetics and flow cytometry
Ari Giagounidis (Düsseldorf)

14:25-14:40  Examining prognostic indicators in MDS
Michael Pfeilstöcker (Vienna)

14:40-14:55  Role of comorbidities and quality of life in prognosis.
New evaluation scales (QUALMS…)
Reinhard Stauder (Innsbruck)

14:55-15:25  ROUNDTABLE:
Response criteria (with recent proposed changes, IWG 2018)
Uwe Platzbecker, Pierre Fenaux, Austin Kulasekararaj, Ari Giagounidis

15:25-15:55  Controversial debate
IS NGS useful in MDS?
Chair: Ari Giagounidis (Düsseldorf)

Audience Voting

15:25-15:30  Introduction
Ari Giagounidis (Düsseldorf)

15:30-15:40  No – Guillermo Sanz (Valencia)
15:40-15:50   Yes – Felicitas Thol (Hannover)

15:55-16:15  Panel discussion

16:15-17:15  SATELLITE SYMPOSIUM:
Title: Exploring the Immune and Inflammatory Microenvironments in the Search for New Therapies
Chair: Uwe Platzbecker (Leipzig)
Speakers: Raphael Itzykson (Paris), Uwe Platzbecker (Leipzig) & David Valcárcel (Barcelona)

This symposium is organized by NOVARTIS

17:20-17:50  Coffee Break

SESSION V – Specific Subtypes of MDS, based on Morphology and Molecular Biology
Chairs: Michaela Fontenay (Paris) & Eric Solary (Villejuif)

17:55-18:00  Introduction
Michaela Fontenay (Paris)
Eric Solary (Villejuif)

18:00-18:15  MDS with Ring sideroblasts
Michaela Fontenay (Paris)

18:15-18:30  CMML and other MDS/MPNs
Eric Solary (Villejuif)

18:30-18:45  MDS with del 5q
Ari Giagounidis (Düsseldorf)

18:45-19:00  Childhood MDS
Charlotte Niemeyer (Freiburg)

SHORT COMMUNICATION:

19:00-19:10  IMPACT of RAS-Pathway Activation on Phenotype and Outcome in Patients with Chronic Myelomonocytic Leukemia and a TET2/SRSF2 Mutation
Klaus Geissler (Vienna)

19:10-19:40  Panel discussion

Saturday, January 30, 2021

SESSION VI – Treatment of MDS
Chairs: Eva Hellström-Lindberg (Stockholm) & Raphael Itzykson (Paris)

13:30-13:35  Introduction
Eva Hellström-Lindberg (Stockholm)
Raphael Itzykson (Paris)

13:35-13:50  Overview of MDS treatment
Eva Hellström-Lindberg (Stockholm)
LIVE Programme
CET Time

13:50-14:05  ESA and other growth factors  Valeria Santini (Florence)
14:05-14:20  HMAs: When and how  Mikkael Sekeres (Miami)
14:20-14:35  Allo Transplantation: When and how?  Marie Robin (Paris)
14:35-14:50  Current treatment guidelines for CMML and rare subtypes  Raphael Itzykson (Paris)

SHORT COMMUNICATION:
14:50-15:00  Circulating Small Noncoding RNAs As Novel Biomarkers in Myelodysplastic Syndromes  Michaela Merkerova (Prague)

15:00-15:30  Panel discussion

15:30-15:40  Coffee break

SESSION VII – Current Progress in the Treatment of MDS
Chairs: Valeria Santini (Florence) & Lionel Adès (Paris)

15:40-15:45  Introduction  Valeria Santini (Florence)
             Lionel Adès (Paris)
15:45-16:00  Higher risk MDS: Lessons from elderly AML
             A renewed role for intensive chemotherapy (CPX 351…)?  Lionel Adès (Paris)
16:00-16:15  Strategies to improve HMA based therapy  Pierre Fenaux (Paris)
16:15-16:30  Management of HMA failure  Valeria Santini (Florence)
16:30-16:45  Novel strategies to treat cytopenia in Low Risk MDS  Uwe Platzbecker (Leipzig)

SHORT COMMUNICATION:
16:45-16:55  Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase Ib Study  Andrew Brunner (Boston)

16:55-17:25  Panel discussion

17:25-18:25  Poster walk
Leaders for Biology: Michaela Fontenay (Paris) & Torsten Haferlach (Munich)
Leaders for Clinical: Eva Hellström-Lindberg (Stockholm) & Valeria Santini (Florence)
### Sunday, January 31, 2021

#### 13:30-14:30  2 Simultaneous Meet the Expert Sessions
- **Treatment of higher risk MDS**
- **Treatment of lower risk MDS**
  
  **Mikkael Sekeres (Miami)**
  **Lionel Adès (Paris)**

#### SESSION VIII – Future Treatments and Treatment Strategies in MDS?
**Chair: Pierre Fenaux (Paris)**

14:35-14:40  **Introduction**  
  Pierre Fenaux (Paris)

14:40-14:55  **Regulatory issues: registration of drugs in haematology**  
  Axel Glasmacher (Bonn)

14:55-15:25  **ROUNDTABLE:**

  **Current MDS/CMML clinical trials in Europe**
  Speakers: Valeria Santini (FISM), David Valcárcel (GESMD), Pierre Fenaux (GFM), Uwe Platzbecker (GMDS and EMSCO)

15:25-15:40  **How to target CHIP?**  
  Klaus Metzeler (Leipzig)

**SHORT COMMUNICATION:**

15:40-15:50  **Cellular and Murine-PDX Models to Evaluate New Therapies for Azacitidine-Resistant MDS**  
  Tomáš Stopka (Prague)

15:50-16:20  **Panel discussion**

#### SESSION IX – Late-Breaking talks
**Chair: Pierre Fenaux (Paris)**

16:20-16:25  **Introduction**  
  Pierre Fenaux (Paris)

16:25-16:40  **Vexas syndrome and MDS**  
  David Beck (Bethesda)

16:40-16:55  **MDS/CMML with TET2 or IDH mutations are associated with Systemic Inflammatory and Autoimmune Diseases and T-cell Dysregulation**  
  Lin-Pierre Zhao (Paris)

16:55-17:25  **Panel discussion**

**17:25 Closing Remarks**  
**Chairs**